Insys Therapeutics (NASDAQ: INSY) reported Q4 EPS of ($0.37), $0.08 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $16.4 million versus the consensus estimate of $18.1 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.